Vifor Builds Its Kidney Disease Focus With $80m Angion Deal
Novel Drug Targets Two Kidney Injury Conditions
Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.
You may also be interested in...
Elicio Uses Reverse Merger With Angion To Go Public At Last
After withdrawing IPO plans last September, Elicio thinks merger with Angion will give it a cash runway through end of 2023 to advance ELI-002, a vaccine for mutant KRAS-driven solid tumors.
Angion’s HGF Mimetic Fails Second Phase II Study, But Not Shuttered Yet
Although ANG-3777, partnered with Vifor, missed its primary endpoint in cardiovascular surgery patients at risk for acute kidney injury, the companies will consider a path forward based on a renal events measure.
Vifor Bulks Up Renal Franchise With Sanifit And Inositec Acquisitions
A couple of months after licensing the late-stage kidney disease drug sparsentan from Travere, the Swiss group has beefed up its nephrology activities by buying Mallorca-based Sanifit and Swiss outfit Inositec.